Drug Approval | April 12, 2025
FDA approves Opdivo plus Yervoy as treatment metastatic colorectal cancer
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
PRX-PLUS has a unique product feature with its deep-impacting formula
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Collaborates with VisionSpring to conduct eye check-up camps for underprivileged children
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
Subscribe To Our Newsletter & Stay Updated
